Artificial intelligence news.
Straight from the original announcements.

Marengo's invikafusp alfa shows first-in-human Vβ T-cell activity in Nature Medicine

October 23, 2026, 13:00By the AI News Bites Editorial TeamSource: PR Newswire
Marengo's invikafusp alfa shows first-in-human Vβ T-cell activity in Nature Medicine
Image: PR Newswire

Marengo Therapeutics has published first-in-human results in Nature Medicine showing that its drug invikafusp alfa can selectively activate and expand Vβ6/Vβ10 T cells in patients with advanced solid tumors. According to the company, the single-agent therapy produced objective responses in heavily pretreated, mostly checkpoint-resistant cancers.

Key points
  • Nature Medicine published first-in-human Phase 1/2 STARt-001 results for Marengo's invikafusp alfa.
  • The drug expanded functional effector and memory Vβ6/Vβ10 T cells in blood and tumors, according to the company.
  • Confirmed objective responses occurred in MSS colorectal cancer and PD-L1-negative non-small cell lung cancer.
  • Cytokine release syndrome was primarily low grade, with no treatment-related deaths and no ICANS cases.
  • Interim STARt-002 results will be presented at SITC 2026, with more clinical data expected in 2027.

What the STARt-001 trial reported

The paper, titled "Bispecific dual T cell agonist invikafusp alfa in solid tumors: the Phase 1/2 START-001 trial," covers the completed Phase 1 dose-escalation and initial Phase 2 expansion cohorts. Marengo, a clinical-stage biotechnology company based in Cambridge, Mass., says it is the first clinical demonstration that germline-encoded Vβ T-cell subsets can be selectively activated and expanded as a cancer therapy. Germline-encoded refers to DNA sequences naturally present in the body from birth.

According to the company, the key findings include:

  • Phase 1 dose escalation was completed without reaching a maximum tolerated dose, and a recommended Phase 2 dose was selected based on safety, pharmacodynamic and antitumor activity data.
  • Selective, dose-dependent expansion of functional effector and memory Vβ6/Vβ10 T cells in both blood and tumors, which the company presents as evidence of target engagement.
  • Confirmed objective responses in heavily pretreated patients with immune checkpoint blockade-resistant tumors, including microsatellite-stable (MSS) colorectal cancer and PD-L1-negative non-small cell lung cancer.

These are settings that have historically shown limited responsiveness to checkpoint inhibition, according to the release.

Safety profile

Marengo describes the safety profile as manageable and consistent with the drug's mechanism of action. Cytokine release syndrome was primarily low grade. The company reports no treatment-related deaths, no treatment-related non-laboratory Grade 4 adverse events and no cases of immune effector cell-associated neurotoxicity syndrome (ICANS).

Lillian L. Siu, M.D., Senior Medical Oncologist at UHN's Princess Margaret Cancer Centre and co-lead author, said the data "provide encouraging clinical evidence that selected Vβ6/Vβ10 T-cell populations can be activated and expanded in patients with advanced cancer." She said the alignment of target engagement, T-cell expansion, safety and responses "provides a rationale for further investigation of this approach." The release discloses that Siu is a scientific advisor to Marengo and holds equity in the company, and that UHN conducts clinical research supported by Marengo.

The science behind invikafusp alfa

Invikafusp alfa (STAR0602) is the lead candidate from Marengo's STAR platform. The company calls it a first-in-class, bispecific dual T-cell agonist. It combines a non-clonal mode of TCR activation with a T-cell co-stimulatory signal in a single molecule, and is designed to promote expansion of clonally diverse, effector memory Vβ T cells.

Marengo says Vβ6/Vβ10 T cells are expressed consistently across multiple tumor types, regardless of patient age or sex, and are enriched among tumor-infiltrating lymphocytes. As a result, the target does not depend on any single tumor-specific mutation or antigen. The company says the publication provides a biological foundation for three approaches: selective activation through STAR, tumor-directed redirection through TriSTAR and selective depletion through MSTAR.

STARt-001 is a global Phase 1/2 trial of invikafusp alfa monotherapy in advanced, antigen-rich solid tumors that are refractory or resistant to PD-1-directed therapy. The Phase 2 portion uses biomarker-enriched cohorts, including TMB-H and MSI-H. The trial is registered as NCT05592626, and Phase 2 expansion is ongoing.

What comes next

Zhen Su, M.D., Marengo's President and Chief Executive Officer, called the publication a moment when "a novel scientific concept becomes a clinically demonstrated therapeutic approach." He said the findings give human proof of concept for the broader platform to activate, redirect or deplete selected T-cell populations.

Marengo said it is presenting updated Phase 2 results at ESMO and advancing a next-generation IO-ADC strategy. It will also present interim Phase 2 results from STARt-002 at the SITC 2026 Annual Meeting. That study is described as the first to combine a Vβ6-selective T-cell agonist with an antibody-drug conjugate in triple-negative and HR-positive/HER2-negative metastatic breast cancer. Further analyses are ongoing, with additional clinical data expected in 2027.

For now, the findings come from an early-stage trial and the results are reported by the company and its collaborators. Further data from the ongoing Phase 2 expansion will show how the activity holds up across tumor types.

Marengo TherapeuticsNature Medicineinvikafusp alfaSTARt-001healthcareresearch findings

Related news

AI review finds major gaps in how medical studies share code
ResearchNovember 19, 2026, 23:15

AI review finds major gaps in how medical studies share code

An MIT and Dana-Farber Cancer Institute-led team used large language models to examine nearly 4,000 clinical prediction studies and hundreds of code repositories. The…

Research
ResearchNovember 19, 2026, 15:00

Aidoc reports faster PE response and broader therapy use with AI workflows

AI-enabled pulmonary embolism workflows were linked to faster PERT activation, higher advanced therapy utilization and shorter hospital stays in research presented at…

Research
ResearchNovember 17, 2026, 16:15

Beat AML reaches 10 years of precision medicine research in leukemia

Blood Cancer United is marking 10 years of its Beat AML Master Clinical Trial, a precision medicine program that has provided genomic analysis to more than 2,000…